We observed that high CDH11 expression correlated with significantly better survival rates in the luminal A (p = 0.0381) and Her-2 enriched (p = 0.0319) subgroups, while no statistically significant correlation was observed between CDH11 expression and luminal B breast cancer patient survival (p = 0.2831) (Figure 1A–C). Here, ERBB2 is linked to breast cancer.